TargetBeta
JAK1
Janus kinase 1 · also JAK1A, JTK3, JAK1B · FERM domain containing
15 programs in company-led studies act on JAK1, from 12 companies: 9 in phase 3, 5 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (13 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| upadacitinibrule | AbbVie | phase 4 | 6424 running | JAK2, JAK3, TYK2 | ChEMBL |
| ruxolitinibrule | Incyte | phase 4 | 9518 running | JAK2, JAK3, TYK2 | ChEMBL |
| baricitinibrule | Eli Lilly | phase 4 | 598 running | JAK2 | NCIt |
| tofacitinibrule | Pfizer | phase 4 | 943 running | JAK2, JAK3, TYK2 | ChEMBL |
| filgotinib maleaterule | Eisai | phase 4 | 21 running | JAK2, JAK3, TYK2 | NCIt |
| jaktinibrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 318 running | FLT3, JAK2, JAK3 | the studies' text |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 464 running | JAK2, JAK3, TYK2 | NCIt |
| ivarmacitinibrule | Jiangsu HengRui Medicine | phase 3 | 254 running | – | NCIt |
| momelotinibrule | GlaxoSmithKline | phase 3 | 174 running | ACVR1, JAK2 | NCIt |
| abrocitinibrule | Pfizer | phase 3 | 303 running | – | ChEMBL |
| FXS5626 | Fosun Pharma | phase 3 | 33 running | TYK2 | the company's pipeline |
| brepocitinibrule | Pfizer | phase 3 | 252 running | TYK2 | NCIt |
| delgocitinibrule | LEO Pharma | phase 3 | 212 running | JAK2, JAK3, TYK2 | ChEMBL |
| golidocitinibrule | Dizal Pharmaceuticals | phase 3 | 102 running | – | NCIt |
| ABBV-7828 | AbbVie | phase 1 | 11 running | – | the company's pipeline |
Conditions their studies are in
- Dermatitis, Atopic, 7 programs
- Arthritis, Rheumatoid, 6 programs
- Colitis, Ulcerative, 5 programs
- Alopecia Areata, 4 programs
- Psoriasis, 4 programs
- Arthritis, Juvenile, 3 programs
- Primary Myelofibrosis, 3 programs
- Vitiligo, 3 programs
- Arthritis, Psoriatic, 2 programs
- Carcinoma, Non-Small-Cell Lung, 2 programs
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026upadacitinib · AbbVie · phase 4 · NCT06389136
- Dec 2026baricitinib · Eli Lilly · phase 4 · NCT07843693
- Dec 2026tofacitinib · Pfizer · phase 4 · NCT07843693
- Dec 9, 2026ruxolitinib · Incyte · phase 4 · NCT07049575
- Dec 11, 2026momelotinib · GlaxoSmithKline · phase 3 · NCT03441113
- Feb 2027jaktinib · Suzhou Zelgen Biopharmaceuticals · phase 3 · NCT07565597
- Feb 28, 2027FXS5626 · Fosun Pharma · phase 3 · NCT07552012
- Mar 2027ivarmacitinib · Jiangsu HengRui Medicine · phase 3 · NCT07251595
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.